From: Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
Trial number | Phase | Patient population | Timing of MRD positivity | Intervention | Primary Outcome | MRD platform |
---|---|---|---|---|---|---|
NCT04809181 | 2 | AML/MDS; < 65 years | After allo-HSCT | Azacitidine + venetoclax | RFS | MFC or RT-qPCR |
NCT04689815 | 2 | NPM1-mutant AML | After consolidation or post-HSCT | Azacitidine + arsenic trioxide | Rate of NPM1 MRD negativity | RT-qPCR |
NCT04712942 | 2 | AML/MDS | After consolidation or post-HSCT | Azacitidine +/− pevonedistat | MRD status | MFC or RT-qPCR |
NCT04086264 | 1/2 | CD123+ AML | After frontline treatment | IMGN632 | Antileukemia activity, MRD levels | MFC |
NCT03769532 | 2 | NPM1-mutant AML; post-HSCT excluded | After chemotherapy | Azacitidine + Pembrolizumab | EFS | RT-qPCR |
NCT04541277 | 2 | AML with PDL1 expression; > 60 years or unfit for intensive chemotherapy; post-HSCT excluded | Not specified | Tislelizumab + HMA +/− CAG | ORR | Not specified |
NCT02684162 | 2 | AML/MDS | After allo-HSCT | Guadecitabine + DLI | CRR, RFS | MFC, RT-qPCR, NGS |
NCT02789254 | 1/2 | AML with FLT3 expression; post-HSCT excluded | After any therapy | FLYSYN | Safety/tolerability | NGS or RT-qPCR |
NCT02520427 | 1 | AML/MDS | Not specified | AMG330 | Safety/tolerability | Not specified |
NCT02275533 | 2 | AML in first remission | After induction or consolidation | Nivolumab | PFS | Not specified |
NCT04623216 | 1/2 | AML in remission after HSCT | After allo-HSCT | Sabatolimab +/− Azacitidine | Safety/tolerability, CRR | Not specified |
NCT02126553 | 2 | AML ≤ 55 years | After induction | Lenalidomide | RFS | MFC, RT-qPCR |
NCT02770820 | 1/2 | Elevated WT1 expression, HLA-A*02.01 genotype | After induction or consolidation | WT1 directed allo-CD8 T cells | Safety/tolerability | MFC, RT-qPCR |
NCT04209712 | 1 | AML (includes children) | After 2 courses of chemotherapy | allo-NK cells | MRD response | MFC |
NCT04632316 | 1/2 | AML/MDS | After consolidation | oNKord | Safety/tolerability, MRD response | MFC |
NCT04284228 | 1/2 | AML/MDS; HLA-A2.01 expression | After allo-HSCT | NEXI-001 | Safety/tolerability, PFS, ORR, OS | MFC or NGS |
NCT03697707 | 2 | AML in first remission | After induction or consolidation | DCP-001 | MRD response | MFC |
NCT04580121 | 1 | HLA-A*02 genotype | Any time | RO7283420 | Safety/tolerability | MFC |
NCT03737955 | 2 | CD33+ AML/MDS/MPN; (includes children) | Any time | Gemtuzumab ozogamicin | MRD response | MFC or RT-qPCR |
NCT04526288 | 2 | AML/MDS | After chemotherapy | allo-HSCT +/− preceding CPX351 | OS | MFC, RT-qPCR, NGS, FISH, or cytogenetics |
NCT03537599 | 1/2 | AML | After allo-HSCT | Daratumumab + DLI | Safety/tolerability, ORR | MFC, NGS, or cytogenetics |
NCT03793517 | 2/3 | Acute leukemias with MLL-r, TLS-ERG, or SIL-TAL1; < 55 years | pre-HSCT | Decitabine + mBu/Cy + allo-HSCT | CIR | Not specified |
NCT03728335 | 1 | IDH2-mutated AML | After allo-HSCT | Enasidenib | Safety/tolerability | MFC, NGS |
NCT04326764 | 3 | AML/MDS | pre-HSCT | Panabinostat | OS | MFC or RT-qPCR |